2021年4期
刊物介紹
Cancer Biology & Medicine is a peer-reviewed open-access journal of Chinese Anti-cancer Association (CACA), which is the leading professional society of oncology in China. The journal quarterly provides innovative and significant information on biological basis of cancer, cancer microenvironment, translational cancer research, and all aspects of clinical cancer research. The journal also publishes significant perspectives on indigenous cancer types in China. The scope covers the following topics: ● Cancer epigenetics ● Cancer stem cell ● Improved in vivo and in vitro cancer models ● Cancer prevention and epidemiology ● Biomarkers for predicting drug response ● Mechanism of drug sensitivity and resistance ● New approaches for cancer detection and diagnosis ● Oncology clinical trials ● Targeted therapy ● Multidisciplinary treatment for cancer Author benefits: ● Easy online submission via Editorial Manager ● Efficient and professional peer-review by expert referees from around the world ● Rapid pre-print online publication ● No charge for publication and Open Access ● International visibility - the journal is available free online
Cancer Biology & Medicine
EDITORIAL
- Cancer immunology and immunotherapy
- Single-cell RNA sequencing reveals spatial heterogeneity and immune evasion of circulating tumor cells
- Epithelial cells mimic immune cells: a novel path toward tumor immunotherapy
- The role of DLL1 in long-term vascular normalization and cancer immunotherapy
- Repurposing glucocorticoids as adjuvant reagents for immune checkpoint inhibitors in solid cancers
- Multiplex imaging reveals the architecture of the tumor immune microenvironment
REVIEW
- Personalized immunotherapy in cancer precision medicine
- Cellular immunotherapy for hematological malignancy:recent progress and future perspectives
- Insights into tertiary lymphoid structures in the solid tumor microenvironment: anti-tumor mechanism, functional regulation, and immunotherapeutic strategies
- Targeting myeloid-derived suppressor cells for cancer therapy
ORIGINAL ARTICLE
- EZH2 identifies the precursors of human natural killer cells with trained immunity
- The commensal consortium of the gut microbiome is associated with favorable responses to anti-programmed death protein 1 (PD-1) therapy in thoracic neoplasms
- Residue substitution enhances the immunogenicity of neoepitopes from gastric cancers
- Culturing adequate CAR-T cells from less peripheral blood to treat B-cell malignancies
- Evaluation of 30 DNA damage response and 6 mismatch repair gene mutations as biomarkers for immunotherapy outcomes across multiple solid tumor types
- Synergistic effects of AAGL and anti-PD-1 on hepatocellular carcinoma through lymphocyte recruitment to the liver
- Ferritin as a diagnostic, differential diagnostic, and prognostic marker for immune-related adverse events
- Analysis of characteristics and predictive factors of immune checkpoint inhibitor-related adverse events
- The prognostic landscape of genes and infiltrating immune cells in cytokine induced killer cell treated-lung squamous cell carcinoma and adenocarcinoma